|
|
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
|
|
|
|
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
|
|
|
|
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
|
|
|
|
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
|
|
|
|
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
|
|
|
|
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
|
|
|
|
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
|
|
|
|
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
|
|
|
|
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
|
|
|
|
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
|
|
|
|
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
|
|
|
|
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
|
|
|
|
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
|
|
|
|
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
|
|
|
|
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
|
|
|
|
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
|
|
|
|
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
|
|
|
|
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
|
|
|
|
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
|
|
|
|
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
|
|
|
|
Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in Canada
|
|
|
|
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
|
|
|
|
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
|
|
|
|
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
|
|
|
|
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
|
|
|
|
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
|
|
|
|
Emergent BioSolutions Reports First Quarter 2024 Financial Results
|
|
|
|
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
|
|
|
|
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
|
|
|
|
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
|
|
|
|
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
|
|
|
|
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
|
|
|
|
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
|
|
|
|
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
|
|
|
|
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
|
|
|
|
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
|
|
|
|
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
|
|
|
|
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
|
|
